{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:26:57Z","timestamp":1777314417404,"version":"3.51.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Spinal muscular atrophy (SMA) linked to chromosome 5q is an inherited progressive neuromuscular disorder with a narrow therapeutic window for optimal treatment. Although genetic testing provides a definitive molecular diagnosis that can facilitate access to effective treatments, limited awareness and other barriers may prohibit widespread testing. In this study, the clinical and molecular findings of SMA Identified\u2014a no-charge sponsored next-generation sequencing (NGS)-based genetic testing program for SMA diagnosis\u2014are reported.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Between March 2018 and March 2020, unrelated individuals who had a confirmed or suspected SMA diagnosis or had a family history of SMA were eligible. All individuals underwent diagnostic genetic testing for SMA at clinician discretion. In total, 2,459 individuals were tested and included in this analysis. An NGS-based approach interrogated sequence and copy number of <jats:italic>SMN1<\/jats:italic> and <jats:italic>SMN2<\/jats:italic>. Variants were confirmed by multiplex ligation-dependent probe amplification sequencing. Individuals were categorized according to genetic test results: diagnostic (two pathogenic <jats:italic>SMN1<\/jats:italic> variants), nearly diagnostic (<jats:italic>SMN1<\/jats:italic> exon-7 deletion with a variant of uncertain significance [VUS] in <jats:italic>SMN1<\/jats:italic> or <jats:italic>SMN2<\/jats:italic>), indeterminate VUS (one VUS in <jats:italic>SMN1<\/jats:italic> or <jats:italic>SMN2<\/jats:italic>), carrier (heterozygous <jats:italic>SMN1<\/jats:italic> deletion only), or negative (no pathogenic variants or VUS in <jats:italic>SMN1<\/jats:italic> or <jats:italic>SMN2<\/jats:italic>). Diagnostic yield was calculated. Genetic test results were analyzed based on clinician-reported clinical features and genetic modifiers (<jats:italic>SMN2<\/jats:italic> copy number and <jats:italic>SMN2<\/jats:italic> c.859G&amp;gt;C).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 2,459 unrelated individuals (mean age 24.3 \u00b1 23.0 years) underwent diagnostic testing. The diagnostic yield for diagnostic plus nearly diagnostic results was 31.3% (<jats:italic>n<\/jats:italic> = 771\/2,459). Age of onset and clinical presentation varied considerably for individuals and was dependent on <jats:italic>SMN2<\/jats:italic> copy number. Homozygous deletions represented the most common genetic etiology (96.2%), with sequence variants also observed in probands with clinical diagnoses of SMA.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Using a high-yield panel test in a no-charge sponsored program early in the diagnostic odyssey may open the door for medical interventions in a substantial number of individuals with SMA. These findings have potential implications for clinical management of probands and their families.<\/jats:p>","DOI":"10.3389\/fneur.2021.663911","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T05:23:20Z","timestamp":1620278600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["SMA Identified: Clinical and Molecular Findings From a Sponsored Testing Program for Spinal Muscular Atrophy in More Than 2,000 Individuals"],"prefix":"10.3389","volume":"12","author":[{"given":"B. Monica","family":"Bowen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Truty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swaroop","family":"Aradhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara L.","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britt A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jody","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Winder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence, and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ejhg.2014.147","article-title":"A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy","volume":"23","author":"Lawton","year":"2015","journal-title":"Eur J Hum Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic, and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.braindev.2008.08.012","article-title":"Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy","volume":"31","author":"Watihayati","year":"2009","journal-title":"Brain Dev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am J Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E1110","DOI":"10.1002\/humu.21173","article-title":"A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy","volume":"31","author":"Vezain","year":"2010","journal-title":"Hum Mutat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/GIM.0b013e318220d523","article-title":"Technical standards and guidelines for spinal muscular atrophy testing","volume":"13","author":"Prior","year":"2011","journal-title":"Genet Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/WCO.0000000000000374","article-title":"Next-generation sequencing in neuromuscular diseases","volume":"29","author":"Efthymiou","year":"2016","journal-title":"Curr Opin Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/NXG.0000000000000412","article-title":"Clinical utility of multigene analysis in over 25,000 patients with neuromuscular disorders","volume":"6","author":"Winder","year":"2020","journal-title":"Neurol Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/gtmb.2019.0282","article-title":"Incorporating spinal muscular atrophy analysis by next-generation sequencing into a comprehensive multigene panel for neuromuscular disorders","volume":"24","author":"Tan","year":"2020","journal-title":"Genet Test Mol Biomarkers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11910-017-0798-y","article-title":"Treatment advances in spinal muscular atrophy","volume":"17","author":"Bharucha-Goebel","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B17","unstructured":"Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1,000 patients","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn."},{"key":"B19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41436-018-0033-5","article-title":"Prevalence and properties of intragenic copy-number variation in Mendelian disease genes","volume":"21","author":"Truty","year":"2019","journal-title":"Genet Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1093\/nar\/gnf056","article-title":"Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification","volume":"30","author":"Schouten","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0143006","DOI":"10.1371\/journal.pone.0143006","article-title":"High-throughput amplicon-based copy number detection of 11 genes in formalin-fixed paraffin-embedded ovarian tumour samples by MLPA-seq","volume":"10","author":"Kondrashova","year":"2015","journal-title":"PLoS ONE."},{"key":"B24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1530\/ey.17.14.3","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature."},{"key":"B25","unstructured":"ViennaR Foundation for Statistical ComputingR: A Language and Environment for Statistical Computing2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1086\/302369","article-title":"Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling","volume":"64","author":"Wirth","year":"1999","journal-title":"Am J Hum Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/humu.10245","article-title":"A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene.","volume":"22","author":"Cusc\u00f3","year":"2003","journal-title":"Hum Mutat."},{"key":"B30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3760\/cma.j.issn.0366-6999.2011.03.012","article-title":"Compound heterozygous mutation in two unrelated cases of Chinese spinal muscular atrophy patients","volume":"124","author":"Qu","year":"2011","journal-title":"Chin Med J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1089\/gtmb.2014.0002","article-title":"Subtle mutation detection of SMN1 gene in Chinese spinal muscular atrophy patients: implication of molecular diagnostic procedure for SMN1 gene mutations","volume":"18","author":"Bai","year":"2014","journal-title":"Genet Test Mol Biomarkers."},{"key":"B32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet Med"},{"key":"B34","unstructured":"National Center for Advancing Translational Sciences.2017"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.1073\/pnas.91.12.5695","article-title":"Effective amplification of long targets from cloned inserts and human genomic DNA","volume":"91","author":"Cheng","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9.27.1","DOI":"10.1002\/0471142905.hg0927s88","article-title":"Spinal muscular atrophy: overview of molecular diagnostic approaches","volume":"88","author":"Prior","year":"2016","journal-title":"Curr Protoc Hum Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nmd.2007.10.003","article-title":"A new splice site mutation in the SMN1 gene causes discrepant results in SMN1 deletion screening approaches","volume":"18","author":"Eggermann","year":"2008","journal-title":"Neuromuscul Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.663911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T05:23:30Z","timestamp":1620278610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.663911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":37,"alternative-id":["10.3389\/fneur.2021.663911"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.663911","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"article-number":"663911"}}